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major vitamin D fracture trials in US and Europe
The DIPART (vitamin D Individual Patient Analysis of Randomized Trials) Group
ABSTRACT
Objectives To identify participants’ characteristics that
influence the anti-fracture efficacy of vitamin D or vitamin
D plus calcium with respect to any fracture, hip fracture,
and clinical vertebral fracture and to assess the influence
of dosing regimens and co-administration of calcium.
Design Individual patient data analysis using pooled data
from randomised trials.
Data sources Seven major randomised trials of vitamin D
with calcium or vitamin D alone, yielding a total of 68517
participants (mean age 69.9 years, range 47-107 years,
14.7% men).
Study selection Studies included were randomised
studies with at least one intervention arm in which
vitamin D was given, fracture as an outcome, and at least
1000 participants.
Data synthesis Logistic regression analysis was used to
identify significant interaction terms, followed by Cox’s
proportional hazards models incorporating age, sex,
fracture history, and hormone therapy and
bisphosphonate use.
Results Trials using vitamin D with calcium showed a
reduced overall risk of fracture (hazard ratio 0.92, 95%
confidence interval 0.86 to 0.99, P=0.025) and hip
fracture (all studies: 0.84, 0.70 to 1.01, P=0.07; studies
using 10 μg of vitamin D given with calcium: 0.74, 0.60 to
0.91, P=0.005). For vitaminD alone in daily doses of 10 μg
or 20 μg, no significant effects were found. No interaction
was found between fracture history and treatment
response, nor any interaction with age, sex, or hormone
replacement therapy.
Conclusion This individual patient data analysis indicates
that vitamin D given alone in doses of 10-20 μg is not
effective in preventing fractures. By contrast, calcium and
vitamin D given together reduce hip fractures and total
fractures, and probably vertebral fractures, irrespective of
age, sex, or previous fractures.
INTRODUCTION
Fragility fractures cause excess mortality, substantial
morbidity, and related health and social service expen-
ditures in older people.1 2 Risk of fracture is higher in
institutionalised older people than in community
dwelling older people of the same age, reflecting a
greater risk of falls and lower bone mineral density.3 4
Vitamin D insufficiency is common in older people,
particularly in residential and care homes. This may
contribute to secondary hyperparathyroidism, bone
loss, impaired neuromuscular function, and an
increased risk of falls and fractures.5-8 This provides
the rationale for using vitamin D to prevent fractures
in older people.
A large randomised controlled trial in women in
French nursing homes or apartments for older people
showed that calcium and vitamin D supplementation
increased serum 25-hydroxyvitamin D, decreased
parathyroid hormone, improved bone density, and
decreased hip fractures and other non-vertebral
fractures.9 Subsequent randomised trials examining
the effect of vitaminD supplementation—with or with-
out calcium—on the incidence of fractures have pro-
duced conflicting results.10 A meta-analysis in 2005
suggested that 17.5-20 μg of vitamin D daily decreased
the risk of hip and non-vertebral fractures, whereas
lower doses (10 μg/day) were ineffective.11 However,
recent meta-analyses indicate that a combination of
calcium and vitamin D reduces hip and non-vertebral
fractures but that vitamin D alone does not.12 13
Study level meta-analyses may be adequate when
estimating a singled pooled treatment effect or investi-
gating study level characteristics, but they can lead to
biased assessments and have limitations in explaining
heterogeneity.14 Analyses of individual patients’ data
offer improved statistical power to investigate whether
treatment effects are related to the patient. We used
individual patient data methods to do a meta-analysis
of randomised controlled trials of vitamin D—with or
without calcium—in preventing fractures and investi-
gated if treatment effects are influenced by patients’
characteristics.
METHODS
Searching and selection criteria
We searched, with no language restrictions, for publi-
cations between January 1966 and July 2008 in Med-
line, Embase, and the Cochrane Central Register of
Controlled Trials by using MeSH terms: [Fractures,
bone] combined with [Vitamin D], [Ergocalciferol] or
[Cholecalciferol]. We also searched for text words in
title and abstract: “Fractu*” or “Bone fractu*”, in com-
bination with “Vitamin D”, ”Cholecalciferol”, or
“Colecalciferol”. We included studies if they were
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randomised (individual or cluster), had at least one
intervention arm in which vitamin D was given and
one arm without vitamin D, used fracture as an out-
come, and included at least 1000 patients. The decision
to include only studies above this size was driven by
concerns that each study,while contributing additional
cases, would also further reduce the mass of shared
study variables for aggregated analysis. We identified
248 abstracts (fig 1); 47 covered clinical trials of vita-
min D with a fracture outcome—36 with n<1000 and
11 with n≥1000. We contacted the corresponding
authors of these 11 trials. Four groups were unwilling
or unable to provide patient level data. 9 15-17 Seven
groups agreed to participate.
Included studies
Six studies were individually randomised.18-23 One
study was cluster randomised at the level of home care
district.24 Of the individually randomised controlled
trials, one was quasi-randomised by birth date.19 Two
studies used a factorial design.22 24 Table 1 gives the
details of the studies. Information on fracture history
was not available in one study.18 All studies reported
incident hip fractures and other non-vertebral frac-
tures. All but one reported on clinical vertebral
fractures.19
Data extraction and validation
We defined a standardised data format and retrieved
datasets electronically in anonymised form from the
corresponding authors. We issued queries to the parti-
cipating centres for discordant data.
Quantitative data synthesis and statistical analysis
Weanalysed data at the level of the patient and accord-
ing to the intention to treat principle. The timescale
used was number of days between date of randomisa-
tion and date of fracture. When the fracture date was
unknown, we used the date of the reporting visit. The
primary end point was any fracture, with hip fracture
and clinical vertebral fracture as secondary end points.
We defined base models by using conditional logistic
regression incorporating known predictors of fracture
risk, which would be expected a priori to contribute to
variation in fracture rates: age, sex, hormone replace-
ment therapy, bisphosphonates, previous hip fracture,
previous vertebral fracture, and “other previous frac-
ture” in adulthood.We added treatment allocation and
interaction terms to this model to identify factors that
significantly modified the response to vitamin D. We
pre-specified the following study level variables for
entry into this interaction analysis: vitamin D daily
dose equivalent, route (oral or intramuscular), and
co-administration of calcium. We then used variables
that interacted significantly to stratify the subsequent
fixed effects Cox fracture-free survival analysis,
which contained a series of dummy variables to
capture residual differences in risk of fracture between
trials. A subgroup analysis by dose (10 μg/day
v 20 μg/day) was pre-specified. We thus classified the
Meyer, Larsen, andWomen’s Health Initiative (WHI)
studies as 10 μg studies and classified the Smith study
(equivalent to 20.5 μg/day), the Lyons study, the
RECORD study, and the Porthouse study (all equiva-
lent to 20 μg/day) as 20 μg studies. Observations were
truncated after 36 months; only the WHI study pro-
vided sufficient patients to populate the analysis
beyond this.
Sensitivity
We did an influence analysis to assess to what extent
conclusions would have been modified by failure to
include one or more individual studies in the analysis.
Recent work suggests that ergocalciferol has half the
calciotrophic effect of cholecalciferol,25 so we
regrouped 20 μg ergocalciferol studies with 10 μg
cholecalciferol studies.
RESULTS
Base model including previous fractures (six studies,
n=65073)
Increasing age (hazard ratio per decade 1.34, 95% con-
fidence interval 1.29 to 1.39), male sex (0.52, 0.47 to
0.58), previous hip fracture (1.86, 1.62 to 2.14), pre-
vious vertebral fracture (1.71, 1.31 to 2.22), other frac-
ture (1.45, 1.35 to1.57), baseline bisphosphonate use
(1.54, 1.22 to 1.92), andbaselinehormone replacement
therapy (0.69, 0.63 to 0.76) contributed significantly to
the risk of any fracture. Strongly statistically significant
interaction terms were route of vitamin D administra-
tion (P=0.02), dosing interval (P=0.02), and co-admin-
istration of calcium (P=0.006), indicating significant
modification of response to treatment (fig 2). Bisphos-
phonate use was of borderline significance (P=0.07).
Previous fractures did not significantly interact with
treatment response (P=0.64 to 0.79 depending on
site), nor did we find an interaction with age, sex, or
hormone replacement therapy. As previous fractures
did not modify the response, we included the Lyons
study,which had no information onprevious fractures,
in the analysis.
Abstracts screened for retrieval (n=248)
Potentially relevant RCTs identified
and screened for retrieval (n=47)
Potentially appropriate RCTs to be
included in meta-analysis (n=11)
RCTs with raw data (n=7)
By study outcome:
  Hip fracture (n=7; 68 517 patients)
  Any fracture (n=7; 68 517 patients)
  Spine fracture (n=6; 67 373 patients)
Not an RCT or no fracture outcome (n=201)
RCTs excluded: Less than 1000 participants (n=36)
RCTs excluded: Unable or unwilling
to provide raw data (n=4)
Fig 1 | Flow chart of analysis. RCT=randomised controlled trial
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Base model not including previous fractures (seven
studies, n=68516)
Decade of age (hazard ratio 1.43, 1.38 to 1.48), male
sex (0.51, 0.46 to 0.56), hormone replacement therapy
(0.65, 0.60 to 0.72), and bisphosphonate use (1.56, 1.25
to 1.95) contributed significantly to the risk of any frac-
ture. Significant interaction terms were route (P=0.03)
and calcium (P=0.04), and borderline significant inter-
action terms were bisphosphonate use (P=0.06) and
interval (daily v non-daily, P=0.12).
Effect of vitamin D treatment (with or without calcium)
Any fracture
The analysis covered 7202 fractures over 177 203 per-
son years. Placebo fracture rates were higher in the vita-
minD trials than in the trials combining vitaminDwith
calcium, as these studies recruited older participants
(table 1). We found no significant effect of vitamin D
without calcium (hazard ratio 1.01, 0.92 to 1.12, P=0.80)
(fig 3). Studies in which vitamin D was combined with
calciumshowed reduced fracture risk (hazard ratio0.92,
0.86 to 0.99, P=0.025). We adjusted the analysis for
study, age, and sex, as well as for baseline hormone
replacement and bisphosphonate use. Stratification by
route of administration showed a significant effect of
oral vitamin D (hazard ratio 0.93, 0.87 to 0.99, P=0.02)
but not injected vitamin D (1.11, 0.95 to 1.31, P=0.20).
Results were unaffected by exclusion of users of hor-
mone replacement therapy and bisphosphonates. We
found no significant treatment by study interaction in
either group of studies (calcium and vitamin D studies
P=0.67 to 0.78, vitamin D studies P=0.14 to 0.44).
Hip fracture
In total, 978 hip fractures were recorded. The risk of
hip fracture was borderline decreased by vitamin D
with calcium (hazard ratio 0.84, 0.70 to 1.01, P=0.07)
(fig 4). Vitamin D studies showed no reduction in risk
of hip fracture (1.09, 0.92 to 1.29, P=0.34). Rates of hip
fracture in the placebo groupwere lower in the calcium
and vitaminD trials than in the vitaminD studies. Stra-
tification by route showed treatment effects short of
statistical significance (oral studies 0.93, 0.81 to 1.06,
P=0.26; intramuscular studies 1.46, 1.00 to 2.13,
P=0.05). We found borderline significant treatment
by study interaction terms for the RECORD study
(P=0.06) and theLyons study (P=0.09). Thiswas driven
by a hazard ratio for hip fracturewith vitaminDof 0.98
(0.76 to 1.27) in the Lyons study (pooled hazard ratio
1.18 (0.94 to 1.48) in the other vitaminD studies) and a
hazard ratio of 1.31 in the RECORD study (pooled
hazard ratio 0.76 (0.62 to 0.94) for the remaining cal-
cium and vitamin D studies).
Clinical vertebral fracture
Only 542 incident clinical vertebral fractures were
reported. We found no significant treatment effect in
calcium and vitamin D studies (hazard ratio 0.85, 0.66
to 1.11, P=0.25) or vitaminD studies (1.12, 0.70 to1.79,
P=0.63) or when stratified by route of administration
(P=0.27 to 0.29).
Vitamin D dose
Irrespective of site of fracture or dose of vitamin D, we
found no significant effect of vitamin D given without
Table 1 | Characteristics of seven included clinical trials
Trial Patient category
Randomisation*
and duration Study arms No Mean (range) age Men (%)
Previous fracture
(%)
Hormone therapy and
bisphosphonates
allowed
Lyons18 Residential home or
sheltered housing
residents (UK)
I; 36 months Oral D2 100 000 IU/4 months
v placebo
3440 83.8 (62-107) 23.7 ND Yes
Meyer19 Nursing home
residents (Norway)
Q; 24 months Oral D3 10 µg/day v placebo 1144 84.7 (47.6-101) 24.1 Hip 26.2; vertebral
ND; other ND
Yes
Porthouse21 General practice
patients with risk
factors (UK)
I: 18-42 months
(median 22.5)
Oral D3 20 µg/day + 1000 mg
calcium v leaflet
3314 76.8 (70.2-102.7) 0 Hip 0.5; vertebral
0.8; other 56.5
Yes
Larsen24 Community dwelling
age ≥66 (Denmark)
C; 42 months Oral D3 10 µg/day + calcium
1000 mg + environmental
intervention v oral D3 10 µg/day +
calcium 1000mg v environmental
intervention v none
9605 75 (66-103) 39.9 Hip 3.3; vertebral
0.7; other 7.4
Yes
RECORD22 Previous
osteoporotic fracture
(UK)
I; 24-62 months
(median 30.4)
Oral D3 20 µg/day + calcium
1000 mg v oral D3 20 µg/day v
calcium 1000 mg v double
placebo
5292 77.5 (70-100) 15.3 Hip 17.1; vertebral
0.2; other 82.8
No
Smith20 General practice
patients presenting
for influenza
vaccination (UK)
I: up to 36 months
(median 36.0)
Intramuscular D2 300 000 IU/
12 months v placebo
9440 80.2 (70.3-100.1) 46.1 Hip 2.8; vertebral
0.6; other 34.8
No
WHI23 Community based,
postmenopausal
womenaged≥50(US)
I: median 85.
4 months
Oral D3 10 µg/day + calcium
1000 mg v placebo
36 282 62.4 (51-81) None Hip 0.6; vertebral
1.5; other 9.8
Yes
ND=not determined.
*I=individually randomised; Q=quasi-randomised by birth date; C=cluster randomised.
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calcium. Vitamin D given as 10 μg with calcium signif-
icantly reduced the risk of any fracture (P<0.05) and
hip fracture (P<0.01). However, the 20 μg dose with
calcium was not associated with a reduced risk of frac-
ture (P=0.58) (table 2).
Absolute risk reduction and numbers needed to treat
We did this analysis only for vitamin D given with cal-
cium, as vitamin D given alone could not be shown to
reduce fracture risk significantly. For any fracture, cal-
cium with vitamin D was associated with an absolute
risk reduction of 0.5% over three years (untreated
event rate 21.0 per 1000 person years, hazard ratio
0.92), corresponding to a number needed to treat of
213 people treated for three years to prevent a fracture.
For people over the ageof 70, the absolute risk reduction
was 0.9% (untreated event rate 29.0 per 1000 person
years, hazard ratio 0.89) and the number needed to
treat was 111. The corresponding numbers for people
with previous fracture (untreated event rate 33.5 per
1000 person years, hazard ratio 0.87), irrespective of
age, were 1.2% and 82. For hip fractures specifically,
the absolute risk reduction was 0.4% for participants
agedover 70 and0.2% inparticipantswith previous frac-
tures, giving numbers needed to treat of 255 and 548.
Sensitivity analysis
In the influence analysis for vitaminD trials, the hazard
ratio remained close to 1.0 irrespective of exclusion of
any one study in both the any fracture scenario and the
hip fracture scenario (fig 5). For calcium and vitaminD
trials, the hip fracture analysis was sensitive to exclu-
sion of contributing studies, leading to a mean effect
close to 1.0 if the Larsen study was excluded. The cor-
responding any fracture analysis was robust, with
mean hazard ratios indicating relatively little
1.04 (0.98 to 1.11)
0.91 (0.75 to 1.12)
0.99 (0.84 to 1.16)
1.55 (0.97 to 2.46)
0.82 (0.71 to 0.95)
0.80 (0.67 to 0.96)
0.80 (0.67 to 0.96)
1.07 (0.82 to 1.39)
0.88 (0.52 to 1.49)
1.00 (0.88 to 1.15)
0 0.5 1.0 1.5 2.0 2.5
Any fracture
0.96 (0.82 to 1.13)
0.93 (0.64 to 1.36)
0.95 (0.53 to 1.69)
2.28 (0.45 to 11.5)
0.69 (0.51 to 0.93)
0.59 (0.39 to 0.90)
0.59 (0.39 to 0.90)
0.90 (0.57 to 1.40)
0.69 (0.19 to 2.53)
1.12 (0.96 to 1.50)
0 0.5 1.0 1.5 2.0 2.5
Hip fracture
Interaction term
  By age
  By sex
  By HRT
  By bisphosphonate
  By calcium
  By daily
  By oral
  By previous hip fracture
  By previous spine fracture
  By other previous fracture
Fig 2 | Interaction tests on logistic regression base model, 36 months intention to treat scenario. Each panel shows summary
of 10 separate interaction analyses, testing statistical significance of each treatment by covariate interaction term added to
base model. Coefficients differing significantly from 1.0 indicate presence of interaction (non-proportional hazards) between
covariate and treatment; coefficients below 1.0 indicate greater treatment response (lower risk of fracture), and coefficients
above 1.0 indicate smaller treatment response (higher risk of fracture). HRT=hormone replacement therapy
Days
A
ny
 fr
ac
tu
re
 p
er
 1
00
0
0 200 400 600 800 1000 1200
0
30
60
90
120
150
D trials
CaD trials
All trials
CaD trials
D trials
0.95 (0.90 to 1.01)
0.92 (0.86 to 0.99)
1.01 (0.92 to 1.12)
0.5 1.0 1.5
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Fig 4 | Cumulative hip fracture incidence for vitamin D (darker
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studies and vitamin D studies are shown separately. Inset
shows treatment effect and 95% confidence intervals.
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difference in effect on point estimates across calcium
and vitamin D studies. The Larsen trial was unique in
using a cluster randomised factorial design, in which
environmental modification and drug review were
added in two study arms.We repeated the hip fracture
analysis across the calcium and vitamin D studies
excluding the two arms of the Larsen study that
included environmental intervention. In this post hoc
analysis, the effect of calcium and vitamin D on hip
fractures had a hazard ratio of 0.82 (0.67 to 0.99,
P=0.045). For vitamin D studies, mean effects were
between 1.00 (exclusion of Smith study) and 1.18
(exclusion of Lyons study). Considering 20 μg of ergo-
calciferol to be equivalent to 10 μg rather than 20 μg of
cholecalciferol affected only the vitamin D studies.
This did not alter the findings (any fracture: hazard
ratio 1.01, 0.90 to 1.14, P=0.83 for lower dose and
1.01, 0.82 to 1.24, P=0.95 for higher dose).
Trials byChapuy, Lips, Trivedi, andLawand collea-
gues did not contribute data to our analysis but
reported similar effects.9 15-17 Inclusion of summary
data from these studies led to a combined hazard
ratio for hip fracture of 1.11 (0.96 to 1.29) for vitamin
D studies and 0.82 (0.72 to 0.95) for calcium and vita-
min D studies.
DISCUSSION
This analysis of individual patients’ data from seven
large fracture trials indicates that vitamin D with cal-
cium reduces the overall risk of fracture, and probably
hip and clinical vertebral fractures, irrespective of sex
and fracture history. For hip fractures, we were able to
showa significant risk reductionwith the lower vitamin
D dose of 10 μg daily given with calcium. Because the
reduction in risk was small (16% or less) and rates of
fracture were low in most studies, the number needed
to treat ranged from more than 200 people (no pre-
vious fracture) to 82 people (with a previous fracture)
treated for three years to prevent any fracture and from
548 (no previous fracture) to 255 people (with a
previous fracture) treated for three years to prevent a
hip fracture. Vitamin D given alone in daily doses of
10-20 μg (400-800 IU) was not shown to be effective.
Comparisons with other studies
Our results agree with three recent meta-analyses that
examined study level data from trials of supplementation
with vitaminD, calcium, or the two combined.121326 The
trials included in these systematic reviews differed
slightly. Two reviews focused on vitamin D and also
found that vitamin D alone was ineffective in preventing
any fracture or hip fractures and that the combination of
calcium and vitamin D showed benefit.1213 Boonen et al
did not examine “any fractures”12; in the Cochrane
review, calcium and vitamin D prevented any fractures
only in people living in institutions.13 By contrast, the
findings of our individual patient data review strongly
favoured calcium and vitamin D for prevention of any
fractures in all populations examined. The Cochrane
review did not find that clinical vertebral fracture was
prevented by vitamin D with or without calcium
supplementation,13 as foundhere, although few trials pro-
vided these data. These two previous systematic reviews
did not assess the influence of dose of vitaminD or com-
pare ergocalciferol with cholecalciferol in detail.
Tang et al systematically reviewed fracture preven-
tion in trials of calcium, with and without vitamin D.26
The overall risk reduction reportedwas 0.90 (95% con-
fidence interval 0.80 to 1.00) for calcium trials and 0.97
(0.92 to 1.03) for calciumandvitaminD trials, although
no significant difference was found between these two
groups. The group of calcium and vitamin D trials in
Tang et al differed from those in the Cochrane review
and the review by Boonen et al and included Larsen,24
without taking account of the cluster design.
Recently, Bischoff-Ferrari and colleagues did a new
study levelmeta-analysis covering 12 randomised con-
trolled trials and concluded that received vitamin D
doses in excess of 400 IU/day prevented non-vertebral
fractures.27 Differences between their conclusions and
ours, although pronounced, are explained by the clas-
sification of the WHI study (400 IU/10 μg vitamin D
plus calcium) as a high dose (765 IU/19 μg) study by
including other vitaminD sources in the treatment arm
(intervention 400 IU plus base 365 IU) and disregard-
ing them in the control arm (intervention 0 IU plus
base 368 IU).
Table 2 | Subanalysis* of anti-fracture efficacy, stratified by vitamin D dose and calcium co-administration
Fracture 10 μg dose 20 μg dose
With calcium: (WHI, Larsen studies) (Porthouse, RECORD-2 studies)
Any Treated 18.7/1000 PY; untreated 20.2/1000 PY; HR=0.91 (95% CI 0.85 to
0.99), P=0.02
Treated 43.2/1000 PY; untreated 51.1/1000 PY; HR 0.95 (0.80 to 1.14), P=0.58
Hip Treated 2.4/1000 PY; untreated 3.0/1000 PY; HR=0.74 (0.60 to 0.91),
P=0.005
Treated 10.3/1000 PY; untreated 9.2/1000 PY; HR 1.30 (0.88 to 1.92), P=0.19
Vertebral Treated 1.4/1000 PY; untreated 1.6/1000 PY; HR=0.86 (0.65 to 1.14), P=0.31 Treated 2.7/1000 PY; untreated 3.1/1000 PY; HR 0.97 (0.48 to 1.98), P=0.93
Without calcium: (Meyer study) (Lyons, Smith, RECORD-1 studies)
Any Treated 85.9/1000 PY; untreated 94.1/1000 PY; HR=0.93 (0.67 to 1.28),
P=0.64
Treated 45.9/1000 PY; untreated 44.4/1000 PY; HR 1.02 (0.92 to 1.14), P=0.69
Hip Treated 61.3/1000 PY; untreated 56.2/1000 PY; HR=1.10 (0.74 to 1.64),
P=0.64
Treated 14.0/1000 PY; untreated 13.0/1000 PY; HR 1.08 (0.89 to 1.30), P=0.45
Vertebral NA Treated 2.4/1000 PY; untreated 2.1/1000 PY; HR 1.10 (0.69 to 1.76), P=0.68
HR=hazard ratio; NA=not applicable; PY=person years.
*Cox proportional hazards model adjusted for patient level covariates of age, sex, study, and use of hormone replacement therapy and bisphosphonate.
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Whether calcium is more important in preventing
fractures than was previously recognised remains to
be determined. An individual patient data meta-analy-
sis is being done on this topic (Mark Bolland, personal
communication, 2009). Calcium and vitamin D are
likely to be more effective in attenuating secondary
hyperparathyroidism, and thus bone turnover and
bone loss, than is vitamin D alone.22 28 Higher doses
of vitamin D than were used in the existing trials may
be needed to suppress bone turnover if calcium is not
co-administered.29 We did not have information
related to baseline vitamin D (diet, sunlight, and sup-
plements) and calcium intake. In most of the included
studies, serum vitamin D was measured only in small
subgroups. Wide variations are likely, owing to inter-
national differences in food fortification and differ-
ences in the age and mobility of study populations.
Previous reports of protective effects of calcium and
vitaminD supplementation in institutionalisedpopula-
tions and lack of effect in non-institutionalised popula-
tions suggest that such differences strongly modify the
anti-fracture efficacy of calcium with vitamin D.915
Within the vitamin D with calcium trials, only the
lower vitamin D dose (10 μg daily) produced a reduc-
tion inhip fracture risk. This is not evidence that a 20μg
daily dose is inferior to a 10 μg daily dose but may
reflect the fact that the trials of 20 μg vitamin D with
calcium attempted to provide fracture prevention at a
threefold higher risk level for hip fractures than did
studies using the lower dose (table 2). Thus, our recom-
mendation would be to use a vitamin D dose of at least
10 μg (400 IU) daily combined with 1000 mg of cal-
cium. In high risk patients, this should be supplemen-
ted by bisphosphonates or other anti-osteoporotic
drugs in accordance with national and international
guidelines.
Strengths and limitations
We were unable to obtain data for four of the 11 iden-
tified studies that fulfilled the inclusion criteria. Our
findings support and further substantiate previous
meta-analyses of study level data that included these
studies.11 13 26 The results of our analysis were robust
in effect size and direction to the exclusion of very
large contributing studies.
We restricted the analysis to 36 months, as only the
WHI studywasofmaterially longer duration.With our
current knowledge on reversal of secondary hyper-
parathyroidism, this time frame seems reasonable
The lack of anti-fracture efficacy seen in the Smith
trial has been suggested to be due to low bioavailability
of the preparation.20 However, although removing this
study from the analysis (fig 5) nominally changed the
anti-fracture effect of the vitaminD only studies from a
small increase to a small decrease in risk, both results
failed to achieve statistical significance.
We could not obtain sufficient information about
compliance to do a per protocol analysis. The effect
size should thus be considered as worst case. We had,
however, pre-specified an intention to treat analysis as
the primary hypothesis test for this study, allowing the
effect size of this intervention to be compared with the
effect sizes of interventions such as prevention of falls
and anti-resorptive drugs.
The Larsen trial was very influential in the analysis
for hip fracture but differed greatly from other studies
in design by being randomised only at the level of
home care districts and by using a factorial design
that included drug review, leaflets, and other environ-
mental interventions.24 As we had access to patient
level information, we were able to repeat the hip frac-
ture analyses without the environmental intervention
arms. However, the calcium and vitamin D arm still
differed from the untreated arm in having the offer of
a drug review. Removing the environmental arms of
the Larsen study did not alter the effect size of the joint
analysis.
Only a single study—the Meyer study—provided
data for vitamin D given alone at the lower dose. The
biological equivalence of ergocalciferol and cholecal-
ciferol doses remains controversial.25 Results, how-
ever, were similar whether the potency of
ergocalciferol was considered to be 100% or 50% of
that of cholecalciferol. Whether intermittent dosing
0.5 1.0 1.5 0.5 1.5
Any fracture
1.0
Hip fracture
CaD
  All
  w/o WHI
  w/o Larsen
  w/o RECORD
  w/o Porthouse
D
  All
  w/o Smith
  w/o Lyons
  w/o Meyer
  w/o RECORD
0.92 (0.86 to 0.99)
0.92 (0.82 to 1.02)
0.93 (0.86 to 1.01)
0.92 (0.85 to 0.99)
0.92 (0.86 to 0.99)
1.01 (0.92 to 1.12)
0.96 (0.84 to 1.09)
1.05 (0.93 to 1.18)
1.02 (0.92 to 1.14)
1.02 (0.91 to 1.14)
0.84 (0.70 to 1.01)
0.88 (0.71 to 1.09)
0.97 (0.75 to 1.26)
0.76 (0.62 to 0.94)
0.83 (0.68 to 1.00)
1.09 (0.92 to 1.29)
1.00 (0.83 to 1.22)
1.18 (0.94 to 1.48)
1.08 (0.89 to 1.30)
1.12 (0.93 to 1.35)
Fig 5 | Sensitivity analysis: influence of removing individual studies from analysis. CaD=calcium and vitamin D trials; D=vitamin
D trials; w/o=without
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can be equated with an average daily dose for vitamin
D remains unresolved. Additional studies would be
needed to clarifywhether the failure of standalone vita-
min D in preventing fractures is due to the route of
administration, the long time interval between doses,
the nature of the vitaminDpreparation, or the propen-
sity for studies of vitamin D to enrol participants of
higher age and greater fracture risk than do studies of
calcium and vitamin D. Although our analysis did not
provide support for any interactionwith age or fracture
history, we cannot distinguish between effects of com-
pound, route, and regimen, as studies of intramuscular
administration never used daily dosing, whereas cal-
cium and vitamin D studies always used oral adminis-
tration and invariably used daily dosing.
We had to make allowance for differences between
studies in available parameters—for example, no data
on fracture history were available in the Lyons study,18
and no data on incident clinical vertebral fractures
were available in the Meyer study.19 We saw no inter-
action, however, between treatment effect and fracture
history in six studies with available data. Studying
adverse events was beyond the scope of this analysis
and would have been difficult to interpret, as the
method of tracking differed more widely between stu-
dies than did reporting of fracture outcomes.
The important strength of this analysis is that we
were able to calculate absolute fracture rates and treat-
ment effects across a wide range of study participants
and interventions, adjust effects for previous fractures
and for the use of bisphosphonates and hormone
replacement therapy at the level of the individual par-
ticipant, account for interactions and study heteroge-
neity, and further substantiate the conclusions of non-
individual patient data meta-analyses.
Conclusions and policy implications
Daily calcium and vitaminD supplementation, even at
doses as low as 10 μg of vitamin D daily, significantly
reduces the risk of fracture, with incidence curves
deviating after about 16 months. Fracture prevention
seemed to be homogeneous across a wide age range
and was unmodified by fracture history or sex. We
must emphasise that this analysis does not allow for a
direct comparison of vitamin D against vitamin D
given with calcium, but only comparisons between
each intervention and no treatment. Whether inter-
mittent doses of vitamin D given without calcium
supplements can reduce the risk of fractures remains
unresolved from the studies in this analysis. Additional
studies of vitaminD are also needed, especially trials of
vitamin D given daily at higher doses without calcium.
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